1.. Introduction {#S5}
================

The term "synthetic cannabinoid" technically refers to any lab-produced compound that affects CB~1~ or CB~2~ function, and includes receptor agonists and antagonists, inhibitors of enzymes, and allosteric modulators ([@R26]). Colloquially, \"synthetic cannabinoid\" is used as an umbrella term that encompasses CB~1~ agonists found in\"Spice\" products. Synthetic cannabinoid receptor agonists (SCRAs) were originally synthesized for research purposes, such as receptor/ligand interaction studies, or to selectively agonize one receptor without affecting the other ([@R2]; [@R30]). Once the chemical structures of SCRAs were published, clandestine chemists hi-jacked the compounds and produced purportedly "safe" alternatives to cannabis ([@R33]).

Though some individuals ingest powdered forms of SCRAs, the most common route of administration is inhalation of smoked or vaporized plant material adulterated with one or more of the SCRAs ([@R60]). Solutions of one or more SCRAs, in a solvent, are often sprayed onto inert plant material, but may also be applied to plant material containing psychoactive alkaloids ([@R13]; [@R15]; [@R25]; [@R60]). Sold under the broad umbrella term "Spice," these synthetic cannabinoid preparations are labeled \"not for human consumption\" to avoid regulation by the Food and Drug Administration ([@R7]), despite their disguised intended use.

SCRAs are broadly categorized into 7 families, based on chemical structure: cyclohexyl-substituted phenols (e.g., CP 47,497), naphtholindoles (e.g., AM-2201, JWH-018), benzoylindoles (e.g., 6-APB), tetramethylcyclopropylindoles (e.g., UR-144, XLR-11), adamantoylindoles (e.g., AKB48), indazole carboxamides (e.g., AB-FUBINACA, AB-PINACA), and quinolinyl esters (e.g., PB-22) ([@R8]; [@R20]; [@R26]). AB-FUBINACA is a member of the indazole carboxamide family of synthetic cannabinoids, which includes two other compounds that have been linked to deaths in the United States: AB--CHMINACA and AB-PINACA ([@R64]). Whereas Δ^9^-tetrahydrocannabinol (THC) is a partial agonist of CB~1~ and CB~2~, many SCRAs act as full agonists at CB~1~, and, in some cases, CB~2~ ([@R18]; [@R20]; [@R26]), and thus SCRAs induce similar cannabimimetic effects to THC, but with increased intrinsic activity ([@R26]; [@R69]).

Classic behavioral and physiological effects of cannabinoids in rodents include catalepsy, antinociception, and hypothermia and depressed locomotor activity, and are typically assessed using the Billy R. Martin tetrad battery ([@R38]; [@R68]). When analyzed in tetrad, both first generation indole (e.g., JWH-018, CP 55,940) and later generation (e.g., AB-PINACA, AB--CHMINACA, AB-FUBINACA) indazole-3-carboxamide-type SCRAs induce catalepsy, antinociception, and hypothermia in mice ([@R9]; [@R69]). SCRAs also have inconsistent effects on locomotor activity. For instance, whereas only high doses of AB-FUBINACA induces immobility in mice ([@R9]; [@R22]; [@R59]), decreased locomotor activity is reported at low and high doses, in rats ([@R35]).

In addition to changes in physiology, cannabinoids have well-established effects on emotion in people and experimental animal models. In humans, acute SCRA use can cause symptoms such as agitation, anxiety, and hallucinations ([@R3]; [@R4]; [@R14]). Several deaths and serious injuries have been reported following acute SCRA use, including self-mutilation and several suicides, most of which have been attributed to hallucinations ([@R23]; [@R42]; [@R47]; [@R63]; [@R64]). In particular, the indazole-3-carboxamide-type SCRAs, are used as street drugs and adulterants in commercial cannabinoid products. For example, MDMB-FUBINACA was identified in e-cigarette liquid ([@R48]) and AB-FUBINACA was detected in a commercial \"cannabidiol oil\" administered to a child ([@R53]). Moreover, SCRAs have shown mixed effects on rodent assays used to screen anxiolytic and antidepressant drugs. For example, in mice, AB-FUBINACA increases time spent in the open arms of the elevated plus maze at low doses, but, has the opposite effect at high doses ([@R59]). In addition, AB-FUBINACA decreases struggling in the forced swim test at a low dose, but increases struggling at a high dose ([@R59]), suggesting that AB-FUBINACA produces dose-dependent locomotor effects observed in other cannabinoids including THC ([@R34]; [@R56]).

Little is known about the effects of repeated SCRA administration. One case report indicates that chronic SCRA use may lead to relatively long-term psychosis ([@R14]). It is plausible that 5HT~2A~ receptors mediate the psychogenic effects of SCRAs, given their upregulation in schizophrenia ([@R19]). More commonly, chronic drug use results in physical dependence. There is evidence, in both preclinical models and from case reports, that repeated use of SCRAs induces dependence, typically evidenced by the development of tolerance and withdrawal following cessation of use ([@R1]; [@R45]; [@R55]; [@R65]). The goals of the present study were to evaluate the acute cannabimimetic effects of the new generation SCRA AB-FUBINACA. To this end, we tested the acute effects of AB-FUBINACA using the classic \"tetrad\" battery. We also monitored the development of physical cannabinoid dependence (i.e., tolerance and withdrawal) following repeated AB-FUBINACA administration in mice, as a predictive proxy of Cannabis Use Disorder in humans. Brain levels of AB-FUBINACA were quantified at various timepoints following injection and matched to \"tetrad\" effects to establish a timecourse.

2.. Methods {#S6}
===========

2.1.. Animals {#S7}
-------------

Adult male and female C57BL/6J mice (The Jackson Laboratory; Bar Harbor, ME) were group housed (4--5 per cage) in Polysulfone plastic cages with food and water available ad *libitum*. Mice were housed in a temperature (20--22 °C) and humidity (50±5%) controlled room, on a 12:12 h light/dark cycle in an AAALAC accredited facility. Mice were randomly assigned to each treatment group, such that each cage contained mice from at least two different treatment groups (i.e., no cage contained only AB-FUBINACA-treated mice). Male and female mice were stratified by sex before random assignment. All experiments were carried out by trained technicians who were blinded to treatment conditions. The Animal Care and Use Committee at West Virginia University approved all experimental protocols prior to the start of any experimental manipulation.

2.2.. Drugs {#S8}
-----------

The SCRA AB-FUBINACA, the phytocannabinoid Δ^9^-THC, and the selective CB~1~ receptor antagonist rimonabant (SR141716A), were generously provided by the National Institute on Drug Abuse (NIDA) Drug Supply Program (Bethesda, MD). All drugs were dissolved in a vehicle composed of 5% ethanol, 5% Kolliphor EL (Sigma-Aldrich, St. Louis, MO), and 90 % normal saline ([@R36]). All solutions were warmed to room temperature before administration at a volume of 10 μL/g body mass.

2.3.. Behavioral assessments {#S9}
----------------------------

### 2.3.1.. Tetrad {#S10}

The "Billy Martin tetrad" is a well-characterized battery of four assays used to evaluate the effects of cannabinoid agonists ([@R38]; [@R68]). It consists of assessments of catalepsy, antinociception, core body temperature, and locomotor activity. Mice were acclimated to the test room for a minimum of 1 h prior to tetrad testing (i.e., in order: locomotor activity, catalepsy, tail immersion, and body temperature) ([@R24]; [@R58]). *Catalepsy* was assessed by gently laying the forepaws of individual mice over a metal bar elevated 3 cm above the benchtop. Total latency to move one or both forepaws off the bar was recorded, with a maximum cutoff of 60 s ([@R39]). *Antinociception* was measured via immersing the distal tip of the tail (i.e., the last 1 cm) into a 56 °C water bath ([@R17]). Latency to remove the tail from the water was recorded, with a maximum cutoff of 10 s. *Hypothermia* was assessed by taking rectal temperature using a micro probe thermocouple thermometer designed for use with mice (BAT-12 with RET-3 probe, Physitemp Instruments Inc., Clifton, NJ, USA). *Spontaneous locomotor activity* was measured by placing individual mice into an empty, plastic test chamber (30 cm W x40 cm L x16 cm H) inside a sound-attenuating chamber outfitted with a fan, white LED lighting and an overhead video camera. Mice were recorded for 5 min and locomotor activity was scored in real time using ANY-maze video tracking software (Stoetling, Wool Dale, IL). Time immobile was determined by setting the tracking parameters to a latency of 1200 ms for 90 % of the mouse image pixels ([@R66]). The test chamber was cleaned between subjects with a paper towel dampened with distilled water. In cases where mice were repeatedly tested, a modified tetrad that excluded locomotor testing was used, because mice quickly habituate to locomotor testing.

### 2.3.2.. Precipitated withdrawal paradigm {#S11}

Mice were weighed daily and injected subcutaneously (s.c.) with AB-FUBINACA (1 or 3 mg/kg; [@R9]; [@R70]) or vehicle every 12 h for 5 days, as described previously ([@R17]; [@R58]; [@R65]). Subcutaneous (s.c.) injection was used for repeated administration in lieu of intraperitoneal (i.p.) injection to decrease risk of injection site irritation or accidental intra-intestinal administration ([@R12]). On the morning of the sixth day, all mice received a final injection of AB-FUBINACA or vehicle. After 30 min, mice received an i.p. injection of rimonabant (3 mg/kg) ([@R38]; [@R65]) to precipitate withdrawal.

### 2.3.3.. Somatic withdrawal signs testing {#S12}

Somatic signs of withdrawal were measured as described previously ([@R65]). Each mouse was placed into an empty, plastic test chamber (20 cm W x20 cm L x15 cm H) inside a sound-attenuating chamber outfitted with a fan and white LED lighting. The apparatus had three clear sides and one mirrored side that faced a video camera to allow for observation of behavior when the mouse faced away from the camera.

Mice were habituated to the test apparatus for 30 min following final AB-FUBINACA or vehicle injection and were then removed and injected with rimonabant (3 mg/kg) or vehicle, as previously reported ([@R58]). The boxes were cleaned between subjects using a paper towel moistened with distilled water. Each mouse was then placed back into the test chamber and video was recorded for 60 min.

Video files were deidentified and scored by a trained observer. A subset of 15 videos was scored by a second observer to ensure inter-rater reliability (r^2^=.97). The dependent variables were (1) incidences of paw tremors and (2) head twitches (i.e., an incidence was scored for 'paw tremor' when the behavior was observed, not for each individual motion). Incidences were considered separate when either (1) another behavior occurred between the incidences, or (2) there was at least 1 s between incidences ([@R58]).

2.4.. Pharmacokinetics: ultrahigh-performance liquid chromatograph-tandem mass spectrometer (UHPLC-MS/MS) analysis {#S13}
------------------------------------------------------------------------------------------------------------------

### 2.4.1.. Reagents {#S14}

AB-FUBINACA and AB--CHMINACA were purchased from Cerilliant Corporation (Round Rock, TX). Acetonitrile, ammonium formate, formic acid, methanol, and water were purchased from Fisher Scientific (Hanover Park, IL, USA). All reagents were ACS grade or better.

### 2.4.2.. Method {#S15}

Adult male and female mice were injected with AB-FUBINACA (3 mg/kg, i.p.) at various timepoints (0.25, 0.5, 1, 4, or 12 h) prior to being euthanized via CO~2~ asphyxia, and brains were placed in 1 mL ice-cold distilled water, homogenized, snap frozen in LN2, and stored at −80 °C until assay. A separate group of mice was injected with vehicle 1 h before tissue collection. Brain tissue samples were homogenized with water (1:3 tissue:water). All samples and controls were kept at −20 °C until analyzed. On the day of analysis, a seven-point calibration curve at concentrations of 1, 2, 5, 10, 20 and 100 ng/g AB-FUBINACA in brain tissue along with a drug free control and a negative control without internal standard (i.e., 1 ng/g AB--CHMINACA) in drug-free serum were prepared. AB-FUBINACA was extracted from tissue using a technique modified from a previously published liquid/liquid extraction method ([@R50]). In brief, 1 ng of AB--CHMINACA, the internal standard, was added to 400 μL of brain homogenate of each calibrator, control or specimen except the negative control. To each specimen, 1 mL of ice-cold acetonitrile was added dropwise while vortexing. The samples were then centrifuged for 5 min at 3000 rpm. After centrifuging the samples were placed in −40 °C freezer for at least 2 h to create clear separation between the aqueous and organic layers. The upper organic layer was transferred to a clean test tube and eva-porated to dryness under a gentle stream of nitrogen in a 40 °C dry bath. The samples were reconstituted with 100 μL of mobile phase and placed in auto-sampler vials for analysis.

The ultrahigh-performance liquid chromatograph-tandem mass spectrometer (UHPLC-MS/MS) analysis was performed on a Sciex 6500 + QTRAP system with an IonDrive Turbo V source for TurbolonSpray^®^ (Sciex, Ontario, Canada) attached to a Shimadzu UPLC system (Kyoto, Japan) controlled by Analyst software (Sciex, Ontario, Canada). Chromatographic separation was performed on an Agilent Zorbax Eclipse XDB-C18 4.6 × 75 mm, 3.5 μ column (Santa Clara, CA). The mobile phase consisted of 10:90 10 mM ammonium formate and 0.1 % formic acid in water:methanol. The UHPLC flow rate was set at 1 mL/min. The mass spectrometer source temperature was set at 650 °C and had a curtain gas flow rate of 30 mL/min. The ionspray voltage was 5000 V, with the ion source gases 1 and 2 at flow rates of 40 mL/min. The acquisition mode used was multiple reaction monitoring (MRM). The retention times for AB-FUBINACA and AB--CHMINACA were 0.9 and 1.2 min, respectively. The declustering potential was set at 30 eV. The following transition ions (*m/z*) were monitored with their corresponding collection energies (eV) in parentheses: AB-FUBINACA, 369\>352 (12) and 369\>324 (19); and AB--CHMINACA, 357\>340 (14) and 357\>312 (24). The total run time for the analytical method was 2.0 min. A linear regression of the peak area of ratios of the quantification and the ISTDs transition ion were used to construct the calibration curves.

2.5.. Statistical analyses {#S16}
--------------------------

Data were analyzed using a between- (e.g., acute AB-FUBINACA, brain metabolism) or within-subjects (e.g., AB-FUBINACA timecourse, tolerance) analysis of variance (ANOVA), with the exception of the withdrawal experiment, which used unmatched *t*-tests to compare the two groups (i.e., veh vs. AB-FUBINACA 1 mg/kg), because an ANOVA of two groups is mathematically equivalent to a *t*-test. Main or interaction effects were followed by either Dunnett (e.g., for dose-response curves, comparing to vehicle treatment) or Bonferonni *post hoc* tests, as appropriate. Differences were considered statistically significant at α = 05.

2.6.. Experimental design {#S17}
-------------------------

Exp 1a. Determine the dose-response relation of the acute effects of AB-FUBINACA (0.1, 1, 2, or 3 mg/kg, i.p.; 30 min pretreatment) or vehicle in male and female mice in the classic tetrad battery, as detailed in 2.3.1 above.

Exp 1b. Challenge the effects of AB-FUBINACA in Exp 1a by using the CB~1~ selective antagonist/inverse agonist rimonabant (3 mg/kg, i.p.). Rimonabant was administered 60 min prior to testing, and either AB-FUBINACA (3 mg/kg, i.p.) or vehicle was administered 30 min prior to testing in modified tetrad (i.e., catalepsy, tail immersion, and body temperature) testing.

Exp 2a. Determine ability to induce AB-FUBINACA withdrawal. To assess withdrawal effects, male and female mice were injected twice daily with AB-FUBINACA (1 mg/kg, s.c.) or vehicle for 5 days. On the 6th day, mice were administered a final dose of AB-FUBINACA (or vehicle) and placed in the test chamber for 30 min. Withdrawal was precipitated with rimonabant (3 mg/kg, s.c.) immediately before mice were returned to the boxes for testing for somatic signs of withdrawal, as detailed in 2.3.2 above.

Exp 2b. Direct replication of Exp 2a, using 3 mg/kg (s.c.) dose of AB-FUBINACA.

Exp 2c. Determine drug tolerance effects of repeated administration of AB-FUBINACA. Following baseline testing, a separate group of male and female mice was administered AB-FUBINACA (3 mg/kg, s.c.) or vehicle every 12 h for 5 days and tested daily in tetrad to determine the degree to which AB-FUBINACA tolerance develops. Mice were tested daily in a modified tetrad battery, starting 30 min after morning drug administration. To probe THC cross-tolerance, approximately 24 h after the final AB-FUBINACA dose, mice were administered vehicle or THC (50 mg/kg, i.p.) and tested in the modified tetrad battery.

Exp 3a. To assess possible pharmacokinetic explanation for the relatively mild AB-FUBINACA withdrawal signs and lack of tolerance, the timecourse of AB-FUBINACA behavioral effects was compared to the well-studied phytocannabinoid, THC. After baseline tests, male and female mice were administered AB-FUBINACA (3 mg/kg, i.p.), THC (50 mg/kg, i.p.) or vehicle and tested repeatedly (0, 0.25, .5, 1, 2, 4, 8, 12, 24, and 48 h post-injection) in a modified tetrad battery. THC dose was chosen based on pilot data ([Fig. S1](#SD1){ref-type="supplementary-material"}).

Exp 3b. Determine brain levels of AB-FUBINACA. Whole brain levels of AB-FUBINACA were quantified, using a parallel group of mice injected with vehicle or AB-FUBINACA (3 mg/kg, i.p.) as detailed in 2.4.2 above. The collection timeline was based on behavioral effects of AB-FUBINACA observed in Exp 3a.

3.. Results {#S18}
===========

3.1.. AB-FUBINACA induces classic cannabinoid effects {#S19}
-----------------------------------------------------

In the tetrad, AB-FUBINACA (3 mg/kg) significantly increased latency in both catalepsy \[F(4,32) = 6.6,p\<.05; [Fig. 1A](#F1){ref-type="fig"}\] and tail immersion \[F(3,35) = 6.9,p\<.05; [Fig. 1B](#F1){ref-type="fig"}\] tests. Mice treated with AB-FUBINACA (≥2 mg/kg) displayed hypothermia \[F(34,35) = 24.9,p\<.05; [Fig. 1C](#F1){ref-type="fig"}\] and increased time immobile \[F(4,35) = 11.4,p\<.05; [Fig. 1D](#F1){ref-type="fig"}\]. To determine the necessity of CB~1~ receptor involvement, male and female mice were administered the CB~i~ selective antagonist rimonabant (3 mg/kg, i.p.) or vehicle 30 min prior to AB-FUBINACA (3 mg/kg, i.p.) or vehicle treatment. Testing was conducted 60 min after rimonabant administration, and 30 min after AB-FUBINACA or vehicle. Again, AB-FUBINACA induced catalepsy \[F(1,24) = 11.8; p\<.05; [Fig. 1E](#F1){ref-type="fig"}\], antinociception \[F(1,24) = 5.6; p\<.05; [Fig. 1F](#F1){ref-type="fig"}\], and hypothermia \[F(1,24) = 60.8; p\<.05; [Fig. 1G](#F1){ref-type="fig"}\], and each of these effects was blocked by rimonabant pretreatment, consistent with a mechanism requiring CB~1~.

3.2.. Repeated administration of AB-FUBINACA induces limited dependence {#S20}
-----------------------------------------------------------------------

Rimonabant significantly increased paw tremors \[t(18) = 3.8,p\<.05; [Fig. 2A](#F2){ref-type="fig"}\] and head twitches \[t(18) = 3.0,p\<.05; [Fig. 2B](#F2){ref-type="fig"}\] in mice repeatedly administered AB-FUBINACA (1 mg/kg) compared to vehicle-treated mice. Similarly, rimonabant precipitated withdrawal increased both paw tremors \[F(2,20) = 9.7,p\<.05; [Fig. 2C](#F2){ref-type="fig"}\] and head twitches \[F(2,20) = 4.3,p\<.05; [Fig. 2D](#F2){ref-type="fig"}\] in the AB-FUBINACA (3 mg/kg, s.c.)-treated mice. It is noteworthy that, using these experimental procedures, mice administered AB-FUBINACA alone did not display spontaneous somatic withdrawal signs ([Fig. 2C](#F2){ref-type="fig"}-[D](#F2){ref-type="fig"}).

Mice repeatedly administered AB-FUBINACA maintained increased effects of catalepsy \[Main effect drug F(1,70) = 31.8,p\<.05; [Fig. 3A](#F3){ref-type="fig"}\], antinociception \[Main effect drug F(1,70) = 15.3,p\<.05; [Fig. 3B](#F3){ref-type="fig"}\], and hypothermia despite five days of treatment \[Interaction F(5,70) = 8.94,p\<.05; [Fig. 3C](#F3){ref-type="fig"}\] indicating that tolerance did not develop. Similarly, THC (50 mg/kg, i.p.) administered on dosing day 6 (i.e., in place of AB-FUBINACA) induced cannabimimetic effects, regardless of AB-FUBINACA treatment history, indicating a lack of cross-tolerance to THC in catalepsy \[p=.48; [Fig. 3D](#F3){ref-type="fig"}\], antinociception \[p=.87; [Fig. 3E](#F3){ref-type="fig"}\], or body temperature \[p = .27; [Fig. 3F](#F3){ref-type="fig"}\].

3.3.. AB-FUBINACA is rapidly cleared from the brain {#S21}
---------------------------------------------------

Although the onset of AB-FUBINACA and THC effects was similar, the duration of cataleptic (1 h vs 2 h for THC) \[F(1,130) = 2.9; p\<.05; [Fig. 4A](#F4){ref-type="fig"}\], antinociceptive (30 min vs. 12 h for THC) \[F(1,130) = 5.7; p\<.05; [Fig. 4B](#F4){ref-type="fig"}\], and hypothermic (2 h vs. 12 h for THC) \[F(1,130) = 19.3; p\<.05; [Fig. 4C](#F4){ref-type="fig"}\] effects of AB-FUBINACA were shorter than the same effects of THC (50 mg/kg).

Given that tetrad effects are brain mediated, whole brain concentrations of AB-FUBINACA were quantified, using a parallel group of mice injected with vehicle or AB-FUBINACA (3 mg/kg, i.p.) 0.25, 0.5, 1, 4, and 12 h prior to tissue collection. The collection timeline was based on behavioral effects of AB-FUBINACA. Brain concentrations of AB-FUBINACA were detectable in whole brain homogenates \[F(5,30)=6.8, p\<0.05; [Fig. 4D](#F4){ref-type="fig"}\]. *Post hoc* analyses revealed significant levels of AB-FUBINACA detected in brain at 15 and 30 min after injection but did not differ from control by 1 h post-injection. In contrast, no drug (i.e., false positives) was detected in the brains of the vehicle control group.

4.. Discussion {#S22}
==============

The current project used the tetrad assay to evaluate the acute cannabimimetic effects of the synthetic cannabinoid receptor agonist (SCRA) AB-FUBINACA. It also evaluated whether the pharmacological effects of AB-FUBINACA underwent tolerance following repeated administration or if the CB~1~ receptor antagonist rimonabant would precipitate withdrawal signs in mice given repeated administration of AB-FUBINACA. AB-FUBINACA produced classic cannabimimetic effects, including catalepsy, antinociception, hypothermia, and hypolocomotion.

A unique finding in this study was the short duration of action of AB-FUBINACA compared with THC as well as earlier developed SCRAs. While the onset of tetrad effects and detectable drug brain levels observed here was similar as previously reported with other SCRAs ([@R54]; [@R51]), we found that AB-FUBINACA effects in the present study abated more quickly than those in the prior study in rats ([@R9]). It is plausible that the differences in observed effect timecourse and magnitude are due to a species differ-ence. Regardless, the relatively short hypothermic timecourse in the present study mirrors published mouse data of similar indazole SCRAs AB-PINACA (10 mg/kg, i.p.) ([@R31]) and AB--CHMINACA (3 mg/kg, i.p.), which induced hypothermia that abated 3 h after injection, whereas the indole SCRA CP55,940 (3 mg/kg, i.p.) induced hypothermia persisted for at least 5 h post-injection ([@R37]). Brain THC levels are detectable for hours after administration in mice ([@R5]) and for at least 1 day in rats ([@R27]). A likely reason for the relatively quick recovery from these compounds is their rapid metabolism, as was illustrated in the analysis of brain homogenate concentrations of AB-FUBINACA (see [Fig. 4](#F4){ref-type="fig"}). Thus, rapid metabolism likely accounts for the relatively short timecourse of injected AB-FUBINACA, which concomitantly may contribute to the apparent lack of tolerance and minimal dependence following its repeated administration.

It is noteworthy that the doses of AB-FUBINACA selected for repeated administration produced a relatively equivalent magnitude of acute effects as the acute effects of THC and other SCRAs, including WIN55,212-2 and JWH-018 ([@R1]; [@R38]; [@R58]; [@R65]), which reliably produce tolerance upon repeated administration. In addition to the relatively short pharmacokinetics of AB-FUBINACA, this agonist possesses considerably higher efficacy at the CB~1~ receptor than THC ([@R26]; [@R69]), which could further contribute to the lack of tolerance observed here. Specifically, as high efficacy agonists produce pharmacological effects with less receptor occupancy than partial efficacy agonists, they are resistant to decreases in CB~1~ receptor expression and function ([@R24]).

That said, the lack of tolerance to the single dose of AB-FUBINACA and cross-tolerance to THC were nonetheless somewhat surprising, as repeated administration of short-acting μ opioid receptor agonists show tolerance and cross-tolerance to longer acting μ opioid receptor agonists. For instance, mice treated chronically with fentanyl displayed dose-dependent cross-tolerance to morphine, a longer acting μ receptor; however, once daily fentanyl injections had no effect on morphine efficacy ([@R61]). Thus, it is plausible that, for tolerance to develop, mice must be exposed more frequently, or perhaps continuously, to AB-FUBINACA (e.g., via osmotic minipump). It has been further suggested that an alternate route of administration (e.g., inhalation) may be a better model of SCRA use because these compounds are generally administered in vapor ([@R37]), which also most closely resembles intravenous administration with regard to speed of delivery to brain. Moreover, the short timecourse of indazole-3-carboxamide-type SCRAs is even further accelerated in an inhaled aerosol model ([@R37]). Although such approaches have limited construct validity and may not reflect patterns of human cannabinoid self-administration, they may contribute to increased understanding of how duration of receptor activation affects drug tolerance. It is also plausible that THC cross-tolerance effects were masked by the use of a relatively high (i.e., 50 mg/kg) dose of THC. Future studies will probe possible ceiling effects by administering lower doses of THC in mice with a history of repeated SCRA exposure.

Although increasing the dose of AB-FUBINACA may result in more pronounced withdrawal effects, higher doses also increase probability of proconvulsant effects, as AB-FUBINACA (6 mg/kg) induces convulsions in male ICR mice ([@R9]). In humans, seizures induced by SCRA use may occur immediately (i.e., within minutes of use) or after a delay of several hours or even days ([@R25]; [@R57]). Although the physiological mechanism(s) are poorly understood, it is hypothesized that off-target effects, lack of quality control, toxicity (absence of mitigating phytocannabinoids and endocannabinoids), ligand bias, or active metabolites/degradants are likely contributing factors ([@R10]; [@R49]). Further complicating mechanistic studies, the metabolites of many SCRAs are active and bind to CB receptors at similar affinities to the parent compound ([@R16]; [@R18]). Previous studies have demonstrated that SCRAs tend to be rapidly metabolized, and that potent metabolites remain in the organism, inter-acting with cannabinoid receptors ([@R6]). This is in contrast to THC, which has only a single known psychoactive metabolite, 11--OH-THC ([@R29]; [@R41]).

Although no statistically significant sex differences were found in present study, it was not a goal to probe sex differences, but rather to ensure that mice of both sexes are included (and clearly reported) in each of our experiments. It is worth noting that the lack of sex differences is consistent with our previous reports of phytocannabinoid (e.g., THC) and SCRA (e.g., JWH-018) withdrawal in mice ([@R66], [@R65]).

Given the unpredictable negative effects of SCRA use in humans, it is tempting to dismiss synthetic cannabinoids as a risk to public health. Yet, it is important to keep in mind that some SCRAs elicit promising pharmacological effects. For example, nabilone (sold as Cesamet) is approved by the US Food and Drug Administration to reduce nausea, vomiting, and wasting in cancer patients. In preclinical models of cancer, JWH-133, a selective CB2 receptor agonist, and WIN55,212--2, a nonselective CB~1~ and CB~2~ agonist, both inhibit breast tumor growth and metastasis *in vitro* and *in vivo* ([@R46]; [@R52]). The therapeutic use of SCRAs has been severely limited, however, by the presence of side effects in preclinical models, including abuse potential and seizures ([@R11]; [@R25]; [@R57]). Recreational use of SCRAs has increased dramatically in recent years, with a concomitant increase in emergency department visits. Few assays currently detect SCRAs in blood or urine ([@R32]; [@R43]; [@R62]), an issue that is compounded by the ever-changing SCRAs used in spice compounds and the difficulty detecting them. Thus, it remains difficult to track exactly which SCRA(s) caused a given adverse health episode. Even determining the dose ingested can be difficult, because the adulterated plant materials often have "hot spots," as a result of uneven distribution, and high inter- and intra-batch variability in quality and dose ([@R21]; [@R28]; [@R40]; [@R67]). Moreover, of the SCRA poisoning cases in which the compounds involved are known, there is often more than one compound present ([@R44]). Thus, the pharmacokinetic and pharmacodynamic features of SCRAs clearly differ from cannabis in their unpredictable effects in humans.

5.. Conclusions {#S23}
===============

The present studies revealed that AB-FUBINACA, a third-generation SCRA, produces cannabimimetic effects that abate much more rapidly than the phytocannabinoid, THC. This rapid offset coincides with drug clearance from the brain, consistent with rapid metabolism and clearance of AB-FUBINACA. As human use of cannabinoids continues, information gained from preclinical studies remains informative for basic understanding of physiological mechanisms and treatments for SCRA use.
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:   Δ^9^-tetrahydrocannabinol

![AB-FUBINACA induces classic cannabinoid effects via CB~1~ receptors. Male and female mice were treated with AB-FUBINACA (0-3 mg/kg, i.p.) 30 min prior to testing in the tetrad battery. AB-FUBINACA induced catalepsy (A) antinociception (B), hypothermia (C), and hypolocomotion (D), consistent with established cannabinoid effects. Pretreatment with the CB~1~ receptor selective antagonist rimonabant (3 mg/kg) blocked each of these effects of AB-FUBINACA (E-G). Data represent mean±SEM (n = 8\[4 m/4f\]/group);\*p\<.05 v. vehicle or baseline.](nihms-1612444-f0001){#F1}

![Rimonabant precipitates AB-FUBINACA withdrawal. Mice were treated with AB-FUBINACA (1 or 3 mg/kg, s.c.) twice daily for 6 days. On the 6th day, mice were injected with rimonabant (3 mg/kg, i.p following the morning injection and evaluated for somatic signs of withdrawal. AB-FUBINACA (1 or 3 mg/kg) increased paw tremors **(A & C)** and head twitches **(B & D)**. Data represent mean±SEM (n = 8-10 \[4-5 m & 4-5f\] /group); \*p\<.05 v. vehicle/rim control group.](nihms-1612444-f0002){#F2}

![Repeated AB-FUBINACA administration does not induce tolerance. Mice were treated twice daily with AB-FUBINACA (3 mg/kg, i.p.) or vehicle for 5 days and assessed in a modified tetrad battery each day, approximately 30 min after injections. AB-FUBINACA continued to induce cataleptic (A), antinociceptive (B), or hypothermic **(C)** effects despite repeated administration. On the 6th day, mice were injected with vehicle or THC (50 mg/kg, i.p.) to evaluate cross-tolerance. Repeated AB-FUBINACA had no effect on THC-induced catalepsy **(D)**, antinociception **(E)**, or hypothermia (F). Data represent mean±SEM (n = 8-10\[4-5 m/4-5f\]/group); \*p\<.05 v. vehicle or baseline.](nihms-1612444-f0003){#F3}

![AB-FUBINACA has short-acting, *in vivo* cannabinoid effects. Male and female mice were injected with AB-FUBINACA (3 mg/kg, i.p.) or THC (50 mg/kg) and tested repeatedly in a modified tetrad battery, following baseline testing. The effects of AB-FUBINACA abated more quickly than the effects of THC in catalepsy **(A)**, antinociception **(B)**, and hypothermia **(C)**. n = 8\[4 m/4f\]/group);\*p\<.05 vs. baseline. A second group of mice was injected with vehicle (i.e., 0 h), 0.25, 0.5, 1, 4, or 12 h prior to tissue collection **(D)**. AB-FUBINACA levels in whole brain homogenates were quantified by UHPLC-MS/MS (n = 6 \[3 m/3f\]/group); \*p\<.05 vs. vehicle group. Data represent mean±SEM.](nihms-1612444-f0004){#F4}
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